Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 310
Selected: 0
NCT IDTitle
NCT05884060Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
NCT04933682Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
NCT04581785Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia
NCT05982938Danicopan Early Access Program
NCT05708573Potential Drug Interaction Between ALXN2040 and Rosuvastatin
NCT01192425Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
NCT00122304Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
NCT05234567A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT02605993Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05319899A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
NCT05288816A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
NCT02220725A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT06578949Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT00040144Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
NCT03403205Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
NCT03661528Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
NCT05202145Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
NCT01193348An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
NCT03181633A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04980248Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
NCT00122317Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01371825Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
NCT02003144An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT04248465An Efficacy and Safety Study of Ravulizumab in ALS Participants
NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT02145182Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
NCT05307978Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT04609670Study of Radiolabeled ALXN2050 in Healthy Adult Males
NCT04369469Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
NCT01757431The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT00670774Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
NCT02614898Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
NCT05047484A Study of Multiple Doses of ALXN2050 in Healthy Adults
NCT04560816A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
NCT01303952Therapy of Chronic Cold Agglutinin Disease With Eculizumab
NCT01895127Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
NCT05314231Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
NCT05840055ACT with NMOSD Patients and Caregivers Pilot Study
NCT01205152Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
NCT03369236A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
NCT06183931Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT05288660A Study of a Single Dose of ALXN1210 in Healthy Participants
NCT07352423Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
NCT03406507A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
NCT00751231A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
NCT04594252Copper Balance in Healthy Participants Administered ALXN1840
NCT07024563Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT04610580Bioavailability Study of 2 Oral Formulations of ALXN1840